Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?
Objectives: Doxorubicin, a commonly used frontline chemotherapeutic agent for cancer, is not without side-effects. The original thinking that the drug causes necrosis in tumours has largely given way to its link with apoptosis over the past two decades. Key findings: More recently, major biomarkers...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Published: |
John Wiley & Sons Ltd.
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/36210 |